Scientists Map the Enzymatic Route That Builds 5-Azacytidine in Nature, Revealing a Rare Skeletal-Editing Reaction

For six decades, one of oncology's most widely used drugs has kept a chemical secret: how a living organism actually builds it. A study published in Nature Catalysis has now identified the biosynthetic gene cluster for 5-azacytidine查看药品详情 and traced the unusual enzymatic cascade that assembles its triazine base, including a rare skeletal-editing reaction that remodels a pyrimidine ring into a 1,3,5-triazine.

5-Azacytidine查看药品详情 is a cytidine mimic in which the carbon at position 5 of the pyrimidine ring is replaced by nitrogen, converting the base into 5-azacytosine. That single atom swap underlies its therapeutic activity: once incorporated into RNA, the analogue disrupts RNA metabolism and traps methyltransferase enzymes, reactivating tumor suppressor genes silenced in cancer cells. The compound was first synthesized by Czech chemists in 1964 and isolated from microbial cultures two years later; it was approved by the FDA in 2004 under the brand name Vidaza查看药品详情 for myelodysplastic syndrome (搜索)搜索该疾病, a group of blood cancers.

Because the molecule was initially reported as a synthetic cytidine analogue, its biosynthesis remained unexplored for decades, probably because it was regarded as a synthetic analogue rather than the product of an evolved metabolic pathway. A team led by Yasushi Ogasawara and Tohru Dairi of Hokkaido University查看公司主页, with Hiroyuki Morita of the University of Toyama查看公司主页 and collaborators across Japan and Taiwan, set out to close that gap. Through comparative genomics and biochemical screening of the producing organism, they pinpointed a set of genes designated azc that is both necessary and sufficient for assembling the triazine nucleobase.

From GTP to a Triamino Pyrimidine

The pathway begins with AzcE (搜索)搜索该靶点, which the researchers identify as a guanosine triphosphate (GTP) cyclohydrolase. GTP cyclohydrolases are best known for opening the purine ring of GTP during folate and riboflavin biosynthesis, but AzcE repurposes this chemistry to generate 2,5,6-triaminopyrimidin-4(1H)-one, a pyrimidine intermediate carrying three amino groups. Structural analysis of AzcE, determined in complex with zinc and its product (PDB 9UJF), revealed how the enzyme positions the substrate for ring opening, providing the first step from a standard nucleotide precursor toward the drug's triazine scaffold.

AzcA Performs Molecular Surgery on a Ring

The centerpiece of the pathway is AzcA (搜索)搜索该靶点, a cupin domain-containing enzyme (搜索)搜索该靶点 that carries out what the authors describe as a skeletal editing reaction. Rather than building the triazine from scratch, AzcA takes the pyrimidine delivered by AzcE (搜索)搜索该靶点 and selectively cleaves its carbon–nitrogen framework, reassembling it into 6-amino-4-oxo-1,4-dihydro-1,3,5-triazine-2-carboxylic acid, with an additional nitrogen inserted into the skeleton.

X-ray crystal structures of AzcA (搜索)搜索该靶点 bound to manganese and to reaction intermediates (PDB 9U8N, 9U8O and 9U8P), combined with biochemical assays and density functional theory calculations, allowed the team to trace the mechanism in atomic detail, showing how the metal center and active-site residues orchestrate bond cleavage and reformation with high selectivity.

An Atypical Use of Thiamine Pyrophosphate

The final step is equally unconventional. The carboxylic acid installed by AzcA (搜索)搜索该靶点 must be removed to yield 5-azacytosine, and the enzyme pair AzcB/C (搜索)搜索该靶点 accomplishes this through a thiamine pyrophosphate查看药品详情-dependent decarboxylation acting on the α-imino carboxylic acid moiety of the AzcA product. Thiamine-dependent enzymes typically handle α-keto acids, so acting on an imino acid represents an atypical use of this cofactor class. Cryo-electron microscopy structures of AzcB/C captured with thiamine pyrophosphate and substrate analogues (PDB 9U8Q, 9U8R and 9U8S) revealed the active-site architecture that stabilizes the reactive intermediates, completing the mechanistic picture of how the triazine base is finished and presumably glycosylated to give the mature nucleoside antibiotic.

Skeletal Editing as a Shared Design Principle

The discovery resonates beyond a single molecule. Synthetic chemists have recently celebrated skeletal editing — the late-stage insertion, deletion or transmutation of single atoms within a molecular framework — as a frontier strategy for drug discovery. The demonstration that a cupin enzyme performs precisely this kind of single-atom logic on a heterocyclic ring during natural biosynthesis shows that nature arrived at the same idea long ago, and suggests that related enzymes scattered across bacterial genomes may perform similar transformations on other scaffolds. Genome mining guided by the azc gene cluster could therefore uncover new triazine and related azine natural products, or inspire engineered enzymes for late-stage functionalization of existing drugs.

Manufacturing and Discovery Implications

There are also practical implications for the drug itself. Current industrial production of 5-azacytidine查看药品详情 relies on multi-step chemical synthesis, and a biosynthetic route defined by just a handful of enzymes offers a potential platform for biocatalytic or fermentative manufacturing, possibly enabling access to analogues that are difficult to make chemically. The work also resolves a long-standing oddity in natural product history: a molecule used daily in oncology wards worldwide turns out to be a genuine bacterial metabolite, forged by enzymes that edit the very skeletons of nucleobases.

The study was conceived and designed by Ogasawara and Dairi, who contributed equally to its leadership; Akari Umezawa, Takeshi Tsunoda and Yu Nakashima contributed equally as authors. Protein Data Bank coordinates for the reported structures are deposited under PDB IDs 9UJF, 9U8N, 9U8O, 9U8P, 9U8Q, 9U8R and 9U8S, with crystallographic data for the compound 7 complex with Ca2+ and oxalic acid available via the Cambridge Crystallographic Data Centre under deposition number 2475067.